Literature DB >> 1511391

Colorectal cancer. Principles of postoperative follow-up.

C J Kelly1, J M Daly.   

Abstract

Monitoring patients after primary large bowel surgery for malignancy is predicated on the concept that early detection of recurrence may provide salvage treatment for cure. Knowledge of the pathologic site and stage provides important information as to the probability of recurrence and the patterns of failure that are likely to occur. Available methods to detect recurrence include clinical, roentgenographic, and serum tests that are done more frequently during the first 2 years after surgery. Monitoring plasma carcinoembryonic antigen levels can lead to identification of asymptomatic recurrences, but there is controversy about the curability of recurrences outside the liver. Newer techniques (such as computed tomographic portography, intraoperative ultrasonography, and radioimmunoguided surgery) provide greater diagnostic accuracy and lead to more appropriate procedures during "second-look" operations. For example, hepatic resection in properly selected patients offers up to a 30% chance of cure and should be pursued aggressively. A search for metachronous cancers by endoscopy also should be done. Knowledge of the potential and patterns of failure can provide a useful guide during the postoperative follow-up care of the patient with large bowel cancer.

Entities:  

Mesh:

Year:  1992        PMID: 1511391     DOI: 10.1002/1097-0142(19920901)70:3+<1397::aid-cncr2820701531>3.0.co;2-a

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Physician follow-up and observation of guidelines in the post treatment surveillance of colorectal cancer.

Authors:  Gabriela M Vargas; Kristin M Sheffield; Abhishek D Parmar; Yimei Han; Kimberly M Brown; Taylor S Riall
Journal:  Surgery       Date:  2013-08       Impact factor: 3.982

2.  Use of carcinoembryonic antigen radioimmunodetection and computed tomography for predicting the resectability of recurrent colorectal cancer.

Authors:  K Hughes; C M Pinsky; N J Petrelli; F L Moffat; Y Z Patt; L Hammershaimb; D M Goldenberg
Journal:  Ann Surg       Date:  1997-11       Impact factor: 12.969

Review 3.  The role of carcinoembryonic antigen monitoring in management of colorectal cancer.

Authors:  M F Mulcahy; A B Benson
Journal:  Curr Oncol Rep       Date:  1999       Impact factor: 5.075

4.  Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer.

Authors:  F L Flanagan; F Dehdashti; O A Ogunbiyi; I J Kodner; B A Siegel
Journal:  Ann Surg       Date:  1998-03       Impact factor: 12.969

5.  Raised carcinoembryonic antigen level as an indicator of recurrent disease in follow up of patients with colorectal cancer.

Authors:  W F Miles; J D Greig; J Seth; C Sturgeon; S J Nixon
Journal:  Br J Gen Pract       Date:  1995-06       Impact factor: 5.386

6.  Cost and effectiveness of follow-up examinations in patients with colorectal cancer resected for cure in a French population-based study.

Authors:  Frédéric Borie; Jean-Pierre Daurès; Bertrand Millat; Brigitte Trétarre
Journal:  J Gastrointest Surg       Date:  2004 Jul-Aug       Impact factor: 3.452

7.  Follow-up in colorectal cancer patients: a cost-benefit analysis.

Authors:  R A Audisio; P Setti-Carraro; M Segala; D Capko; B Andreoni; G Tiberio
Journal:  Ann Surg Oncol       Date:  1996-07       Impact factor: 5.344

8.  Postsurgical surveillance of colon cancer: preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest x-ray, and colonoscopy.

Authors:  R A Graham; S Wang; P J Catalano; D G Haller
Journal:  Ann Surg       Date:  1998-07       Impact factor: 12.969

9.  FDG-PET scan in patients with clinically and/or radiologically suspicious colorectal cancer recurrence but normal CEA.

Authors:  Ismet Sarikaya; Mark Bloomston; Stephen P Povoski; Jun Zhang; Nathan C Hall; Michael V Knopp; Edward W Martin
Journal:  World J Surg Oncol       Date:  2007-06-07       Impact factor: 2.754

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.